Javascript must be enabled to continue!
FGF21 improves ventricular remodeling in TAC induced heart failure rats
View through CrossRef
Abstract
Background: Studies have found that elevated serum fibroblast growth factor 21 (FGF21) levels in patients with heart failure (HF) predicted poor prognosis. While preclinical studies have found that FGF21 plays a favorable role in the pathophysiological process of heart failure. Clinically, this increase in serum FGF21 seems to contradict the results of preclinical studies, therefore, the purpose of this study was to analyze whether FGF21 can improve ventricular remodeling in the HF rats, thereby improving cardiac function.
Methods: The HF model of transverse aortic coarctation (TAC) was conducted and divided into 4 groups: sham group (Sham), TAC model group (TAC), TAC+FGF21 neutralizing antibody (FGF21nAb) group (TAC+FGF21nAb), and TAC+FGF21nAb+recombinant mouse FGF21 (rmFGF21) group (TAC+FGF21nAb+rmFGF21). Echocardiography, hematoxylin-eosin staining (HE), Masson staining, enzyme linked immunosorbent assay (ELISA) and western blot (WB) were used to evaluate the changes of cardiac structure and function in each group. The adenosine triphosphate (ATP) in myocardial tissue was determined by colorimetry. The level of reactive oxygen species (ROS) in myocardial tissue was determined by chemiluminescence method.
Results: Serum FGF21 level in the TAC+FGF21nAb group was significantly lower than that in the TAC group (29.42±8.54pg/ml vs1886.65±169.51 pg/ml, P<0.001). Compared with the Sham group, left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS)were significantly decreased (P<0.001), with a significant increase in serum B-type natriuretic peptide (BNP) levels (P<0.05) in the TAC group and TAC+FGF21nAb group. However, after 3 weeks of rmFGF21 treatment, LVEF and LVFS were significantly increased (P<0.001), and serum BNP was significantly decreased (P<0.001). Compared to the Sham group, the heart mass significantly increased (P<0.01), myocardial cell hypertrophy, inflammatory cell infiltration,a large amount of fiber deposits in myocardium and around blood vessels, ROS level significantly increased (P<0.001), and the ATP content was significantly decreased (P<0.001) were observed in the TAC group and TAC+FGF21nAb group. While rmFGF21 could improve the above phenomenon.
Conclusion: FGF21 can improve ventricular remodeling and cardiac function in HF rats by anti-inflammation, anti-fibrosis, reducing oxidative stress and regulating energy metabolism.
Title: FGF21 improves ventricular remodeling in TAC induced heart failure rats
Description:
Abstract
Background: Studies have found that elevated serum fibroblast growth factor 21 (FGF21) levels in patients with heart failure (HF) predicted poor prognosis.
While preclinical studies have found that FGF21 plays a favorable role in the pathophysiological process of heart failure.
Clinically, this increase in serum FGF21 seems to contradict the results of preclinical studies, therefore, the purpose of this study was to analyze whether FGF21 can improve ventricular remodeling in the HF rats, thereby improving cardiac function.
Methods: The HF model of transverse aortic coarctation (TAC) was conducted and divided into 4 groups: sham group (Sham), TAC model group (TAC), TAC+FGF21 neutralizing antibody (FGF21nAb) group (TAC+FGF21nAb), and TAC+FGF21nAb+recombinant mouse FGF21 (rmFGF21) group (TAC+FGF21nAb+rmFGF21).
Echocardiography, hematoxylin-eosin staining (HE), Masson staining, enzyme linked immunosorbent assay (ELISA) and western blot (WB) were used to evaluate the changes of cardiac structure and function in each group.
The adenosine triphosphate (ATP) in myocardial tissue was determined by colorimetry.
The level of reactive oxygen species (ROS) in myocardial tissue was determined by chemiluminescence method.
Results: Serum FGF21 level in the TAC+FGF21nAb group was significantly lower than that in the TAC group (29.
42±8.
54pg/ml vs1886.
65±169.
51 pg/ml, P<0.
001).
Compared with the Sham group, left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS)were significantly decreased (P<0.
001), with a significant increase in serum B-type natriuretic peptide (BNP) levels (P<0.
05) in the TAC group and TAC+FGF21nAb group.
However, after 3 weeks of rmFGF21 treatment, LVEF and LVFS were significantly increased (P<0.
001), and serum BNP was significantly decreased (P<0.
001).
Compared to the Sham group, the heart mass significantly increased (P<0.
01), myocardial cell hypertrophy, inflammatory cell infiltration,a large amount of fiber deposits in myocardium and around blood vessels, ROS level significantly increased (P<0.
001), and the ATP content was significantly decreased (P<0.
001) were observed in the TAC group and TAC+FGF21nAb group.
While rmFGF21 could improve the above phenomenon.
Conclusion: FGF21 can improve ventricular remodeling and cardiac function in HF rats by anti-inflammation, anti-fibrosis, reducing oxidative stress and regulating energy metabolism.
Related Results
Regulation of glucose homeostasis by FGF21
Regulation of glucose homeostasis by FGF21
<p>Fibroblast Growth Factor 21 (FGF21) is an endocrine hormone derived from the liver that exerts pleiotropic effects on the body to maintain overall metaboli...
FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1
FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1
Abstract
Fibroblast growth factor 21 (FGF21) is a pleiotropic hormone, secreted mainly by the liver, considered as a major regulator of energy homeostasis. Recent research ...
Exercise, FGF21, and PGC-1 : roles in hepatic metabolism
Exercise, FGF21, and PGC-1 : roles in hepatic metabolism
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] The liver is instrumental in maintaining euglycemia during times of fasting and exercise, and in-turn exercis...
FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling
FGF21 expression and release in muscle cells: involvement of MyoD and regulation by mitochondria-driven signalling
Although the liver is generally considered the main site of production of FGF21 (fibroblast growth factor-21), high FGF21 levels have been found to be associated with neuromuscular...
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
Fibroblast growth factor 21 (FGF21) is a liver-secreted peptide hormone reportedly improving metabolic homeostasis, partly via reduced hunger for sugar, fat, protein and alcohol. E...
Leptin as a Potential Regulator of FGF21
Leptin as a Potential Regulator of FGF21
Background/Aims: Fibroblast growth factor 21 (FGF21), a potent metabolic regulator, has been shown to improve insulin sensitivity in animal models of insulin resistance. Several st...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
FGF21 Attenuates Neurodegeneration though Modulating Neuroinflammation and Oxidant-stress
FGF21 Attenuates Neurodegeneration though Modulating Neuroinflammation and Oxidant-stress
Abstract
Background
It is reported that FGF21 can repair nerve injury, but the specific mechanism is less studied. The present study was designed to investigate the effects...

